Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Revenue | ¥13,011 | ¥14,034 | ¥12,025 | ¥11,906 |
| % Growth | -7.3% | 16.7% | 1% | – |
| Cost of Goods Sold | ¥10,453 | ¥11,772 | ¥10,028 | ¥9,777 |
| Gross Profit | ¥2,558 | ¥2,262 | ¥1,997 | ¥2,129 |
| % Margin | 19.7% | 16.1% | 16.6% | 17.9% |
| R&D Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥1,558 | ¥1,510 | ¥1,600 | ¥1,507 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥2 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥1,560 | ¥1,510 | ¥1,600 | ¥1,507 |
| Operating Income | ¥998 | ¥752 | ¥397 | ¥622 |
| % Margin | 7.7% | 5.4% | 3.3% | 5.2% |
| Other Income/Exp. Net | ¥54 | -¥203 | ¥133 | -¥135 |
| Pre-Tax Income | ¥1,052 | ¥549 | ¥530 | ¥487 |
| Tax Expense | ¥376 | -¥127 | ¥158 | ¥247 |
| Net Income | ¥696 | ¥691 | ¥309 | ¥291 |
| % Margin | 5.3% | 4.9% | 2.6% | 2.4% |
| EPS | 23.21 | 22.71 | 20.33 | 18.96 |
| % Growth | 2.2% | 11.7% | 7.2% | – |
| EPS Diluted | 23.21 | 22.71 | 20.33 | 18.96 |
| Weighted Avg Shares Out | 30 | 30 | 15 | 15 |
| Weighted Avg Shares Out Dil | 30 | 30 | 15 | 15 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥1 | ¥0 | ¥0 |
| Interest Expense | ¥30 | ¥38 | ¥34 | ¥34 |
| Depreciation & Amortization | ¥1,083 | ¥1,124 | ¥1,105 | ¥1,052 |
| EBITDA | ¥2,083 | ¥1,697 | ¥1,668 | ¥1,674 |
| % Margin | 16% | 12.1% | 13.9% | 14.1% |